OFFICIAL NOTICE
DECISION OF A DEPUTY COMMISSIONER OF PATENTS
Patent: No. 602638 in the name of Pfizer, Inc
Title: Triazole Antifungal Agents
Action: Request under s.70 for an extension of term of the patent
Decision: Issued 4 June 2004
Abstract
Application to extend the term of a patent under s.70. A subsequent 'selection' patent had previously had its term extended on the basis of an ARTG registration of the substance voriconazole. The same ARTG registration was being relied upon to extend the term of the 'parent' patent. During consideration of the request, the examiner objected that the relevant substance was not 'in substance disclosed' in the specification.
· where there is a selection patent that specifically claims a substance, there is a fundamental inconsistency with an assertion that the particular substance is in substance disclosed in the parent patent.
· The resolution of this inconsistency is necessarily an evidentiary issue. In the context of a request for extension of the term of a patent (which is likely to occur some considerable time following the filing of the respective patents), the following are relevant:
·The selection patent will likely have been applied for and granted at a time closer to the relevant date for construing the disclosure of the earlier patent, and therefore has weight in construing the disclosure of the earlier patent by reason of its temporal proximity – especially in comparison with evidence of skilled persons as of ‘today’;
·A selection patent that specifically claims a substance constitutes rebuttable evidence that that substance was not in substance disclosed in the parent patent;
·In circumstances where the substance is neither specifically identified or exemplified in the parent patent, the burden of rebutting the evidence provided by the selection patent necessarily lies with the person arguing that the relevant substance is in substance disclosed in the parent patent.
· Evidence provided was insufficient to rebut the evidence as provided by the existence of the selection patent. Extension refused.
PATENTS ACT 1990
DECISION OF A DEPUTY COMMISSIONER OF PATENTS
Re:Patent No. 602638 by Pfizer, Inc, and a request under s.70 for an extension of term of the patent.
BACKGROUND
In September 2002 Pfizer Pty Limited obtained ARTG Registration in respect of the therapeutic good VFEND voriconazole. The compound voriconazole has the chemical name 2R,3S-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)-butan-2-ol.
On 27 Feb 2003 Pfizer, Inc requested an extension of term of patent 625188 on the basis of that ARTG registration. In that patent, voriconazole is specifically claimed in claim 12 – as the 4th of six specific alternative compounds.
Patent 625188 is in the nature of what is commonly referred to as a selection patent. At its commencement it states:
Some of the compounds of the present invention are disclosed in a general sense in our European patent application No 89307920.2 (EP-A-0357241) equivalent to patent application No 38930/89 but none of them are specifically described or exemplified therein.
The term of this patent was extended on 24 October 2003.
On 27…
Keep reading for free
Create a free CaseChat account to read Pfizer, Inc and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2004] APO 12
- Decision Date
CaseChat Overview and Summary
The key legal issue was how to determine whether a substance was "in substance disclosed" in a patent specification, especially when the substance was not specifically identified or exemplified. The Commissioner considered the principles established in previous cases, particularly that the test for "in substance disclosed" is essentially the same as the "real and reasonably clear disclosure" test of fair basis. The Commissioner also noted that a selection patent, which specifically claims a substance, constitutes rebuttable evidence that that substance was not in substance disclosed in the parent patent. In circumstances where the substance was neither specifically identified nor exemplified in the parent patent, the burden of rebutting the evidence provided by the selection patent necessarily lies with the person arguing that the relevant substance is in substance disclosed in the parent patent.
The Commissioner found that the evidence provided by the patentee was insufficient to rebut the evidence as provided by the existence of the selection patent. The Commissioner concluded that the selection patent constituted clear evidence that the substance was not in substance disclosed in the parent patent. The evidence of Dr. Stamford, while showing that the substance fell within the scope of the generic disclosure and that there was an enabling disclosure, did not address the question of whether the substance was "in substance disclosed". The Commissioner therefore refused the request for an extension of the term of the patent.
The Commissioner's decision underscores the importance of the temporal proximity and forensic value of a selection patent in determining whether a substance was "in substance disclosed" in a parent patent. The existence of a selection patent that specifically claims a substance is prima facie evidence that the substance was not in substance disclosed in the parent patent, and this evidence may be rebutted only by clear and convincing evidence. The Commissioner's decision also highlights the need for evidence that goes beyond mere grammatical construction to establish the disclosure of a substance in the absence of explicit identification or exemplification.
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi